Castle, W. M., Jukes, A. J., Griffiths, C. J., Roden, S. M., & Greenstreet, Y. L. (1992). Safety of ondansetron. European Journal of Anesthesiology, 9(Suppl. 6), 63-66.
2.
Davis, R., Whittington, R., & Bryson, H. M. (1997). Nefazadone: A review of its pharmacology and clinical efficacy in the management of major depression. Drugs, 53, 608-636.
3.
Figueredo, E., & Canosa, L. (1999). Prophylactic ondansetron for post operative emesis: Meta analysis of its effectiveness in patients with and without a previous history of motion sickness, European Journal of Anesthesiology, 16, 556-564.
4.
Gratz, I., Allen, E., Afshar, M., Joslyn, A. F., Buxbaum, J., & Prilliman, B. (1996). The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron, Anesthesia and Analgesia, 83, 565-569.
5.
Pigott, T. A. (1999). Gender differences in the epidemiology and treatment of anxiety disorders. Journal of Clinical Psychiatry, 60(suppl 18), 4-15.
6.
Simpson, K. H., & Hicks, F. M. (1996). Clinical pharmacokinetics of ondansetron: A review. The Journal of Pharmacy and Pharmacology, 48, 774-781.
7.
Sirota, P., Mosheva, T., Shabtay, H., Giladi, N., & Korczyn, A. D. (2000). Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. American Journal of Psychiatry, 157, 287-289.
8.
Toren, P., Laor, N., Cohen, D. J., Wolmer, L., & Weizman, A. (1999). Ondansetron treatment in patients with Tourette’s syndrome. International Clinical Psychopharmacology, 14, 373-376.
9.
Tyers, M. B., Bunce, K. T., & Humphrey, P. P. (1989). Pharmacological and anti-emetic properties of ondansetron. European Journal of Cancer and Clinical Oncology, 25(suppl 1), S15-S19.
10.
Wilde, M. I., & Markham, A. (1996). Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs, 52, 773-794.
